Despite such potential shortcoming referable to all cancers, small molecule uPA inhibitors were shown to produce significant antineoplastic effects with other types of solid tumors [39,40,41], which suggests the ability of ATC cells to compensate for the uPAS functions turned off by drug treatment and to activate resistance mechanism(s). The gene discussed is PLAU; the disease is cancer.